Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA)

DSpace/Manakin Repository

Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA)

Citable link to this page

 

 
Title: Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA)
Author: Brinton, Eliot A.; Mason, R. Preston

Note: Order does not necessarily reflect citation order of authors.

Citation: Brinton, Eliot A., and R. Preston Mason. 2017. “Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA).” Lipids in Health and Disease 16 (1): 23. doi:10.1186/s12944-017-0415-8. http://dx.doi.org/10.1186/s12944-017-0415-8.
Full Text & Related Files:
Abstract: The omega-3 fatty acid eicosapentaenoic acid (EPA) has multiple actions potentially conferring cardiovascular benefit, including lowering serum triglyceride (TG) and non-high-density lipoprotein cholesterol (non-HDL-C) levels and potentially reducing key steps in atherogenesis. Dietary supplements are a common source of omega-3 fatty acids in the US, but virtually all contain docosahexaenoic acid (DHA) in addition to EPA, and lipid effects differ between DHA and EPA. Contrary to popular belief, no over-the-counter omega-3 products are available in the US, only prescription products and dietary supplements. Among the US prescription omega-3 products, only one contains EPA exclusively (Vascepa); another closely related prescription omega-3 product also contains highly purified EPA, but is approved only in Japan and is provided in different capsule sizes. These high-purity EPA products do not raise low-density lipoprotein cholesterol (LDL-C) levels, even in patients with TG levels >500 mg/dL, in contrast to the increase in LDL-C levels with prescription omega-3 products that also contain DHA. The Japanese prescription EPA product was shown to significantly reduce major coronary events in hypercholesterolemic patients when added to statin therapy in the Japan EPA Lipid Intervention Study (JELIS). The effects of Vascepa on cardiovascular outcomes are being investigated in statin-treated patients with high TG levels in the Reduction of Cardiovascular Events With EPA-Intervention Trial (REDUCE-IT).
Published Version: doi:10.1186/s12944-017-0415-8
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282870/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:31731743
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters